Message From the Editor-in-Chief

Editorial Statistics and Best Reviewers Award for 2014 ····· 225

Focus Reviews on Heart Failure

Cell Therapies for HF ····· 229
 Devices in Heart Failure ····· 237
 Direct Cardiac Reprogramming for Heart Repair ····· 245

Focus Reviews on Ischemic Heart Disease

DAPT for CAD ····· 255
 BVS in STEMI ····· 263

Reviews

Stroke Prevention by Cardiologists ····· 271
 MicroRNA-33a/b in Lipid Metabolism ····· 278

Editorials

Reliable Detecting Method for Fatal Arrhythmias ····· 285
 Regional Impact of Registry Data ····· 287
 Tests and Antidote for NOACs ····· 289
 NOACs in Japanese Patients ····· 292
 Effective Renal Artery Stenting in J-RAS Study ····· 295
 Underuse of Prophylactic ICD in Japan ····· 297
 FFR-CT and Clinical Utility ····· 300
 Plasma MicroRNA-100 and Plaque Vulnerability ····· 303
 Perspectives on AF Ablation ····· 305
 Anticoagulation for Lower-Risk AF ····· 307

Original Articles

Arrhythmia/Electrophysiology
 Risk Assessment in BrS ····· 310
 T-Wave Variability for VA Prediction ····· 318
 Anticoagulation in Valvular AF ····· 325
 Hemostatic In Vitro Reversal of Rivaroxaban ····· 331
 NOAC in Japanese AF Patients ····· 339
 Minimal Sedation During AF Ablation ····· 346

Cardiovascular Intervention
 Renal Artery Stenting Outcome in J-RAS Study ····· 351
 HATTRICK-OCT Trial ····· 360

Effect of rivaroxaban on platelet and fibrin interactions with damaged vessels exposed to flowing blood. (A) Control, (B) Rivaloxaban. See figure legend on page 335.

Images in Cardiovascular Medicine

Eccentric MR on TEE ····· 439
 OCT Assessment of BMS in the SFA ····· 441

Letters to the Editor

Late-Phase TE After AF Catheter Ablation ····· 444
 Reply ····· 445
 Atrial Arrhythmias in Arrhythmogenic Cardiomyopathy ····· 446
 Reply ····· 447

ISSN-1346-9843